Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Rizzardini, Giuliano" or (type any "bookEditor journalEditor issueEditor" and editor="Riz...

Add to list
- Journal Article
- A1
- open access
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Franco Maggiolo, Giuliano Rizzardini, Jean‐Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove (UGent) , Juan Berenguer, Michelle L. D'Antoni, Christiana Blair, Susan K. Chuck, et al.

(2022) HIV MEDICINE.
Add to list
- Journal Article
- A1
- open access
Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV aged ≥ 65 years : week 48 results of a phase 3b, open-label trial

Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove (UGent) , Juan Berenguer, Michelle L. D’Antoni, Christiana Blair, Susan K. Chuck, et al.

(2021) INFECTIOUS DISEASES AND THERAPY. 10(2). p.775-788
Add to list
- Journal Article
- A1
- open access
Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks : results of the DRIVE-SHIFT trial

Margaret Johnson, Princy Kumar, Jean-Michel Molina, Giuliano Rizzardini, Pedro Cahn, Markus Bickel, Josep Mallolas, Yan Zhou, Cristiana Morais, Sushma Kumar, et al.

(2019) JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 81(4). p.463-472
Add to list
- Journal Article
- A1
- open access
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients : results from the GUARD-C cohort

Graham R. Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K. Rajender Reddy, Ludovico Tallarico, Mitchell L. Shiffman, Silke Ahlers, Georgios Bakalos, et al.

(2016) PLOS ONE. 11(3).

Academic Bibliography

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV aged ≥ 65 years : week 48 results of a phase 3b, open-label trial

Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks : results of the DRIVE-SHIFT trial

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients : results from the GUARD-C cohort

Contents

Support

Contact